Ocular Manifestations in Systemic Lupus Erythematosus

Sutasinee Boonsopon1,2, Armin Maghsoudlou1,2 and Charles Stephen Foster1,2,3*

1Massachusetts Eye Research and Surgery Institution (MERSI), Cambridge, MA, USA
2Ocular Immunology and Uveitis Foundation, USA
3Harvard Medical School, Cambridge, USA

Corresponding author: Charles Stephen Foster, Massachusetts Eye Research and Surgery Institution, 355 Main Street, 8th Floor, Cambridge, MA 02142 USA, Tel: 617-621-6377, Fax: 617-494-1430; E-mail: sfoster@mersi.com

Received date: February 20, 2015; Accepted date: March 24, 2015; Published date: March 30, 2015

Keywords: Systemic lupus erythematosus; Antiphospholipid syndrome; Ocular manifestations; Vision threatening

Introduction

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that has multisystem involvement. It is a challenging disease to diagnose, assess and manage. Many factors of this disease have been postulated including genetic susceptibility, environmental effects, and disturbances in both innate and adaptive immunity [1]. The highest prevalence has been reported in Italy, Spain, Martinique, and the African-Caribbean population [2]. The eye is not a primary target of SLE, but it can be affected in a variety of ways resulting in significant ocular morbidity [3]. This can occur in up to one third of patients and it can be a marker for overall systemic disease activity [4]. Eye symptoms are easily neglected by patients who are overwhelmed with major organ involvement when their disease is active, but delayed diagnosis and treatment may lead to permanent eye damage and visual loss. This article aims to review the ocular manifestations in SLE that are related to the disease itself, manifestations related to antiphospholipid syndrome, and manifestations secondary to medications. Early detection, early diagnosis and prompt referral to ophthalmologists can prevent permanent visual loss in some instances.

Pathophysiology and Immunology

Many mechanisms are involved in SLE related ocular lesions. These include immune complex deposition and other antibody related mechanisms, vasculitis, and thrombosis [5]. Cytokine dysregulation, polyclonal B-cell activation, autoantibody production, and increased immune complex formation due to aberrations involving hyperactive B cells, T cells, and cells of the monocyteic lineage are also postulated [6]. Deficiencies in components of the compliment cascade are well known to the development of SLE. Some of the strongest associated risk loci identified through genome-wide association studies are ITGAM, FcyR, PRDM1-ATG5, and TNFAIP3 [1]. Immune complex deposition has been identified in blood vessels of the conjunctiva, retina, choroid, sclera, and ciliary body [7]. Circulating antibodies such as antiphospholipid antibodies (in particular interest in β2-glycoprotein) [1] and antineuronal antibodies also play a role by increased liability to thrombosis [8]. The role of anti-neuronal antibodies is evidenced in neuropsychiatric lupus [9]. There were 20 autoantibodies detected in the serum or cerebrospinal fluid of patients with neuropsychiatric lupus and they were categorized into brain-specific and systemic autoantibodies. Brain-specific autoantibodies included those binding neuronal, brain reactive (BRAA), N-methyl-d-aspartate receptor (NMDA), ganglioside, microtubule-associated protein 2 (MAP-2), neurofilament, and glial fibrillary acidic proteins. The most common autoantibodies in patients with neuropsychiatric lupus however, were anticardiolipin antibodies [1]. Lupus is also strongly associated with defects in apoptotic clearance [10] Moreover, medications (such as hydralazine, D penicillamine, anti-TNFα inhibitor), hormonal influences (pre-puberty, puberty, pregnancy, menstrual cycle, menopause), and other factors such as sunlight have all been implicated in disease exacerbation [4]. Ultraviolet light is the most well described environmental trigger of systemic lupus erythematosus. Both ultraviolet A2 and ultraviolet B exposure can exacerbate skin disease in patients with the disorder [11]. However, the consequent avoidance of sunlight can lead to vitamin D deficiency, which is inversely related to disease activity [12].

Mechanism of Disease

Disregulation of the immune system was found in SLE patients. Multiple autoantibodies that have been implicated in the disease include autoantibody against double-stranded DNA, Ro, La, Sm, NMDA receptor, phospholipid, and α-actinin [4]. The explanations of tissue damage cause by autoantibodies have two major theories. The first theory suggested that anti-double stranded DNA antibodies bind to circulating nucleosomes to form immune complexes that then get

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease manifest with multiple organ system involvement. Even though the eye is not part of the diagnostic criteria, once it gets affected, it will alter patients’ quality of life. The purpose of this review is to point out the significance of ocular manifestations in SLE and to emphasize the importance of possible blinding complications such as peripheral ulcerative keratitis, scleritis, and SLE retinopathy/chorioidopathy. The condition can be even worse when SLE is accompanied with antiphospholipid syndrome. In addition to the disease itself, several treatment agents that are used in SLE are responsible for vision threatening conditions; thus they have to be given with caution because of potential side effects, including cataract, glaucoma, and chloroquine maculopathy.
deposited in end-organ capillary beds such as the renal glomerulus and activate immune/inflammatory responses [13]. The second hypotheses that these autoantibodies cross-react with normal renal proteins causing tissue destruction [14]. The source of autoantigens that trigger the formation of the aforementioned antibodies is thought to arise from apoptotic cells, with phagocytosis by macrophages. Depression of such complement factors is an independent risk factor for the development of SLE [15] Mass production of autoantibodies relies on multiple factors, which have each independently been targeted as a potential immunotherapy in the treatment of lupus. Important steps include T-cell activation via antigen binding to the T-cell receptor and proper co-stimulation; T-cell activation of B-cell; production of cytokines such as TNF-α, TNF-γ, IL-10, and B lymphocyte stimulator [4].

During the past few years, several mechanisms have been proposed for a potential role of Neutrophil Extracellular Traps (NETs) in the etio-pathogenesis of SLE. When neutrophils undergo mitosis, histones are highly susceptible to acetylation and methylation of certain residues that were reportedly associated with apoptosis [16-18]. The increased content of acetylated and methylated residues on histones from NETs of SLE patients may, therefore, indirectly increase the immune-stimulatory potential of NETs via an enhanced binding of antimicrobial peptides within the NETs. However, it appears that modified histones themselves are also highly immune-stimulatory [19].

Epigenetics and Lupus

Pathophysiological mechanisms in SLE involve both genetic and environmental factors. Genome-Wide Association (GWA) screening for several thousand bi-allelic variants in case-control studies has identified over 30 genes involved in SLE [20]. A role for epigenetic dysregulation in the pathogenesis of SLE was suggested more recently [21]. Epigenetics is the study of transmissible and reversible changes in gene expression that are not accompanied with alterations in nucleotide sequences. Epigenetic information is carried chiefly by DNA itself, histones, and noncoding RNAs [22]. Epigenetic dysregulation in lupus is related to DNA methylation abnormalities (hypomethylation), biochemical changes in histones (hypacyetlation of the histones H3 and H4 in CD4+ T cells from patients with SLE, as well as a negative correlation between the level of H3 histone acetylation and disease activity [23] More recent studies showed IL-17A overexpression related to biochemical changes in the histones located near the corresponding locus [24]), and dysregulation of microRNA (especially a role of MiR-146a) [25].

Autoimmunity and Oxidatively Modified Autoantigens

Reactive oxygen species (ROS) are oxygen-based molecules possessing high chemical reactivity. These include free radicals (superoxide and hydroxyl radicals) and non-radical species (hydrogen peroxide) which can be produced even at basal conditions by a number of ways [26]. In SLE and other diseases, significantly higher 4-hydroxy-2-nenal-modified protein levels occur in children with lupus. SOD1 activity was decreased in lupus [27]. Malondialdehyde and conjugated dienes were significantly elevated in lupus patients compared to controls. Antibodies to SOD1 were significantly increased in SLE patients and are potentially responsible for the increased oxidative damage seen [27]. Oxidatively modified LDL’s have been shown to elicit autoantibodies and oxidant stress has been attributed to the development of anti-phospholipid antibodies. Elevated levels of anti-oxLDL autoantibodies occur in SLE patients [28]. Studies show that anti-oxLDLs positively correlate with antiphospholipid antibodies and anti-β-2-glycoprotein. Antibodies to oxLDL that are cross-reactive with phospholipids are thought to be due to binding to oxidized phospholipids. Circulating oxLDL/β-2-glycoprotein complexes and IgG immune complexes containing oxLDL/β-2-glycoprotein occur in SLE and/or phospholipid syndrome [29]. Increased levels of 8-oxo-deoxyguanine (8-oxodG) have been found in lymphocytes from patients with SLE. An investigation of blood monocytes from patients with SLE showed an impairment in the removal of 8-oxodG as a result of a deficient repair system [30].

Diagnostic Criteria

The latest revision and development of classification criteria for SLE has been the publication of the Systemic Lupus International Collaborating Clinics (SLICC) classification criteria in 2012 [1,31]. This is show in Table 1. Interestingly, ocular manifestations are not part of the criteria.

### Table 1: Diagnostic Criteria for Systemic Lupus Erythematosus

<table>
<thead>
<tr>
<th>Clinical criteria</th>
<th>Immunological criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute cutaneous lupus, including lupus malar rash, bullous lupus, toxic epidermal necrolysis variant of SLE, maculopapular lupus rash, photosensitive lupus rash, or subacute cutaneous lupus (psoriasiform of annular polycyclic lesions, or both)</td>
<td>Leukopenia (&lt;4,000 cells per μL at least once) or lymphopenia (&lt;1,000 cells per μL at least once)</td>
</tr>
<tr>
<td>Chronic cutaneous lupus, including classic discoid rash (localized and generalized), hypertrophic lupus, lupus panniculitis, mucosal lupus, lupus erythematosus tumidus, chilblains lupus, and discoid lupus/lichen planus overlap</td>
<td>Thrombocytopenia (&lt;100,000 cells per μL) at least once</td>
</tr>
<tr>
<td>Oral ulcers and nasal ulcers</td>
<td></td>
</tr>
<tr>
<td>Non-scarring alopecia</td>
<td></td>
</tr>
<tr>
<td>Synovitis involving two or more joints and at least 30 minutes of morning stiffness</td>
<td></td>
</tr>
<tr>
<td>Serositis</td>
<td></td>
</tr>
<tr>
<td>Renal (urine protein to creatinine ratio or 24 hours urine protein) representing 500 mg protein per 24 hours or red blood cell casts.</td>
<td></td>
</tr>
<tr>
<td>Neurological: seizures, psychosis, mononeuritis multiplex, myelitis, peripheral and cranial neuropathy, acute confusional state.</td>
<td></td>
</tr>
<tr>
<td>Hemolytic anemia</td>
<td></td>
</tr>
<tr>
<td>Leukopenia (&lt;4,000 cells per μL at least once) or lymphopenia (&lt;1,000 cells per μL at least once)</td>
<td></td>
</tr>
</tbody>
</table>
Ocular Manifestations

SLE may affect almost any part of the eye and visual pathway. Ocular manifestations include eyelids, orbit, lacrimal system, ocular surface, glaucoma, cataract, uveitis, retinal vasculature, choroid, and cranial nerves [3-5,32]. The most common ocular involvement is dry eye syndrome or keratoconjunctivitis sicca, and the most common vision threatening condition is retinopathy [3-5].

External eye diseases

Eyelid disease: Discoid lupus rash over the eyelids present as discrete raised scaly lesions [5], which are often mistaken for chronic blepharitis and eczema, and may lead to permanent sequelae such as maceration and cicatrization ectropion. Lupus rash of this site is rare compared to other sun-exposed areas such as the head, the face, and the neck [4]. Histopathologic study shows a hyperkeratotic epithelium with liquefactive degeneration of the basal layer and a dense perivascular/periappendageal lymphocytic infiltration [33,34]. Kopsachilis et al. recommended all patients with chronic blepharitis who do not respond to common therapy should be examined for possible facial lesions, and biopsy with direct immunofluorescence staining should be considered [35]. Direct immunofluorescence (DIF) is use to detect deposits of the immunoglobulins IgG, IgM, and in rare cases, IgA, as well as deposits of the complement component C3 at the dermoeidermal junction [36]. Diagnosis can be made by serological blood test, but only 20% of discoid lupus patients have a positive Antibody titre (ANA) [35]. Other laboratory tests that are recommended to confirm the diagnosis of cutaneous lupus erythematosus despite ANA are Erythrocyte Sedimentation Rate (ESR), C-reactive protein (CRP), complete blood count (CBC), liver enzymes, renal function parameters and urinalysis. Special tests after a histologically confirmed diagnosis of cutaneous lupus erythematosus are serum complement factors C3 and C4, antiphospholipid antibodies, immunoglobulins, rheumatoid factor, thyroid stimulating hormone (TSH) and thyroid antibodies, Venereal Disease Research Laboratory (VDRL), glomerular filtration rate (GFR), 24-hour urine protein, glucose-6-phosphate dehydrogenase activity [36]. Autoantibodies against double-stranded DNA and Sm are in the majority of cases associated with SLE and are not characteristic for any of the cutaneous lupus subtypes [37]. One further possible target of autoantibodies is annexin 1, a significant higher level of anti-annexin 1 antibody was observed in DLE patients, suggesting that anti-annexin 1 antibody might be a new diagnostic marker for DLE [38]. These lesions usually respond well to systemic therapy with hydroxychloroquine 200 mg orally twice per day if started early, but not topical anti-inflammatory therapy [39]. Ultraviolet light avoidance is also recommended [35].

Lacrimal system disease: Dry eye syndrome is the most common ocular presentation of SLE, present in approximately 25-35% of the patients, and is often associated with secondary Sjögren’s syndrome, which is characterized by lymphocytic infiltration of the exocrine glands [3,40]. Dry eye in SLE patients is mainly caused by a decrease in tear production leading to ocular discomfort, irritation, and burning sensation [3]. Biswas et al identified that the anti-Sjögren’s syndrome type B (SSB), the same substance as a cytoplasmic antigen La, namely the SSB/La antigen, was associated with the decreased phagocytic efficiency of neutrophils in patients with SLE [41]. A form of dry eye can be treated with artificial tear drops [5]. Corticosteroid drops are one of the most commonly used drugs for the treatment of any ocular surface inflammation. This treatment prohibits cell adhesion molecule ICAM-1, MMPs, prostaglandin, cytokine, and chemokine production and release, and stimulates lymphocyte apoptosis. Complications of corticosteroid eye drops should be taken into consideration since dry eye is a chronic problem. Therefore, they should be used as an acute phase treatment option in patients who are not relieved by other treatments [42]. The first topical cyclosporine eye drop, Restasis™ 0.05%, received FDA approval in 2002 for the treatment of inflammation in dry eye syndrome. It decreases expression of inflammation markers such as IL-2, IL-17, and IFN-α, which take place in HLA-DR and T-lymphocyte activation on ocular surface tissues of dry eye patients [43]. A decrement in IL-6 and activated lymphocytes, reduction of MMP-9 expression in conjunctival epithelial cells were reported with topical cyclosporine in moderate to severe dry eye patients [44,45]. Cyclosporine eye drop can also increase goblet cell density and immunoregulator TGF-β2 production, decrease in squamous metaplasia, ocular surface restoration with an improvement in corneal sensitivity and inhibition of apoptosis [46-48]. Tetracycline and derivatives act by inhibiting bacterial flora which produces lipolytic exoenzyme and lipase enzyme. They decrease collagenase activity, phospholipase A2 and MMPs activities, and inhibit IL-1 and TNF-α production in corneal epithelium and ocular surface structures. They also decrease lipase activity, regulate meibomian lipids, and decrease MMP-8 levels [49]. Oral tetracycline can be used 250 mg 4 times daily, or as doxycycline or minocycline 100 mg once or twice daily [42]. Autologous serum is rich in epitheliotropic factors, neurotrophin, vitamin A, immunoglobulin, and extracellular matrix proteins. They support epithelial cell proliferation and the normal morphology of corneal epithelial cells with this rich context [42]. In severe dry eye secondary to inflammatory conditions, systemic immunosuppressive agents can be considered [50].

Orbital disease: This is a rare condition and can present as orbital mass, periorbital edema, orbital myositis, panniculitis; previously called lupus erythematosus profundus (nodular inflammation of adipose tissue), acute orbital ischemia and infarction [5,51,52]. Clinical
presentation may be ptosis, proptosis, orbital pain, limitation of extraocular movements, and enophthalmos. Histopathologic features of lupus-related vasculitis or panniculitis is characterized by a lymphocytic reaction with a marked number of plasma cells, necrosis, hyalinization of fat and a secondary vasculitis with thickened arterial walls and occlusion. Positive immunofluorescent testing may help in making diagnosis [52]. Immunohistochemical study shows lymphocyte infiltration (OKT4, OKT8 OKT11, and HLA-DR positive cells) and element of the monocyte-macrophage lineage (Leu M3 and Leu M5 positive). Immunofluorescent IgG, IgM, C3 and C4 deposits were found in blood vessel walls of the deep dermis [53]. Treatment is with immunosuppression [5].

**Anterior eye segment manifestations**

**Conjunctiva:** Chronic conjunctivitis is infrequent [3]. Symblepharon has been reported, especially in association with discoid lupus erythematosus of the eyelids [39]. Immunopathologic studies examining actively inflamed conjunctiva in SLE-associated peripheral ulcerative keratitis, scleritis, and cicatrizng conjunctivitis showed subepithelial and perivascular cellular infiltration and granuloma formation, as well as immune deposits at the epithelial basement membrane and in vessel walls, compatible with an immune complex-mediated disease [54,55]. Nonsteroidal anti-inflammatory agents or antimalarial therapy may be sufficient in relatively mild disease [54].

**Corneal disease:** In addition to dry eye and punctate epithelial erosion, breakdown of corneal epithelium can cause recurrent corneal erosion, and uncommonly, the inflammatory process in SLE can also affect the perilimbal capillary arcades and cause Peripheral Ulcerative Keratitis (PUK), which is rarely associated with necrotizing scleritis, as a result of severe systemic vaso-occlusive disease [54]. Involvement of the deep corneal layers, presented as interstitial keratitis is rarely reported [56]. Treatment strategy for PUK is systemic corticosteroids plus a cytotoxic agent during the acute phase of the disease and lubrication of corneal surface concomitantly. Collagenase inhibitors or collagenase synthetase inhibitors may be of limited benefit in reducing additional stromal ulceration. Topical steroids are not appropriate because these drugs inhibit new collagen production and thereby increase the risk of perforation [57].

**Episclera:** Episcleritis is a benign inflammation of the episclera, usually present with mild, if any, irritation and redness due to injection of the superficial blood vessels [5]. Systemic associations are rare [3]. The incidence in adult patients with SLE has been reported at 2.4% [58]. Treatment options include observation or topical/systemic nonsteroidal anti-inflammatory drugs [4].

**Scleral disease:** Scleritis is a painful, potentially sight threatening disorder and occasionally requires urgent assessment. It is less frequent than episcleritis but it can cause severe ocular morbidity [3]. Anterior scleritis may present as diffuse (Figure 1), nodular, or necrotizing scleritis, which may result in significant destruction, leaving an area of scleral thinning [5]. Redness is cause by injection of deep episcleral vessels. On the other hand, posterior scleritis is usually not associated with redness, because it affects sclera posterior to the equator of the globe. Presenting symptoms are pain and blurry vision, which is commonly caused by exudative retinal detachment, papillitis, and/or cystoid macular edema [4,5]. Prognosis of scleritis depends specifically on the systemic disease with which it is associated. The scleritis associated with SLE usually runs a fairly benign course. Immunosuppression is essential, and treatment usually entails steroid therapy in combination with immunomodulatory therapy [59]. Tectonic scleral or peripheral corneal grafting may be necessary [60].

**Anterior uveitis:** SLE is a rare cause of anterior uveitis [3], but Drosos et al. believed that it is not an uncommon manifestation of SLE [32]. Hypopyon uveitis in a SLE patient was also reported in 2005 and prompt systemic immunosuppressive therapy was considered [61].

**Cataract:** The frequency of cataract in SLE patients ranges from 5-32%. It is not only iatrogenic steroid use in SLE that is associated with cataract formation, but also hypertension (especially high systolic blood pressure) and high level of SLE disease activity. The most important risk factor for cataract is the cumulative dose of corticosteroid [62]. In the general population, the relationship between hypertension and cataract has been inconsistent [63,64].

**Glaucoma:** Measuring intra-ocular pressure in SLE patients is challenging; the biomechanical properties of the cornea are altered compared to normal individuals. Intra-ocular pressure readings may be underestimated in SLE eyes [65]. The first report of open angle glaucoma in SLE was believed to be a report in 1971; the author speculated that an inflammatory connective tissue disorder such as SLE had occurred within the aqueous outflow channels and resulted in glaucoma, but this can also had been aggravated by systemic corticosteroid [66]. Not only secondary open angle glaucoma can be found in SLE patients, but also angle closure glaucoma secondary to choroidal effusion or posterior scleritis [67,68].

**Posterior eye segment manifestations**

**Retina:** Retinal diseases affect around 10% of SLE patients, reflecting a reduction in frequency associated with improved control of systemic disease [5]. The retinal signs often parallel the severity of systemic inflammation, and may indicate control of the systemic disease [69,70].

**SLE retinopathy:** There is a strong correlation between presence of retinopathy and central nervous system disease such as cerebrovascular attacks, dementia, seizure, chorea, and transverse
myelopathy [71-73]. Mild retinopathy may be asymptomatic but more severe disease may cause loss of vision, field defects, distortion or floaters [5]. The earliest findings are small intraretinal hemorrhages and cotton wool spots [74]. This may resemble Purtcher-like retinopathy with characteristics of multiple areas of polygonal retinal whitening between the retinal arterioles and venules, usually accompanied by superficial cotton wool spots at the posterior pole [73].

The pathogenesis is characterized by the activation of immune cells and various cytokines, as well as the production of auto-antibodies and immune complex [75]. Fluorescein angiogram may show multifocal areas of capillary non-perfusion, supporting the theory of microembolization in Purtcher-like retinopathy. Complement activation does not appear to be a sufficient condition for the development of Purtcher-like retinopathy. Capillary endothelial damage and hyperviscosity have also been suggested to play roles in Purtcher-like retinopathy [73]. In the majority of cases, prognosis is excellent, but severe vaso-occlusive retinopathy often results in poor visual and systemic prognosis [76]. Proliferative retinopathy may occur in up to 72% of such cases, often with ensuing vitreous hemorrhage, retinal traction and retinal detachment [5].

Systemic therapy with steroid is required when severe manifestations are presented, initial treatment is usually with oral corticosteroids (e.g. prednisolone 1 mg/kg/day), but may be preceded by intravenous methylprednisolone [5,77]. Immunosuppression has been successful in improving the appearance of the retinopathy; however, visual recovery has only been reported in few cases. The permanent loss of visual acuity is likely due to retinal ischemia [4]. Laser therapy, intravitreal anti-vascular endothelial growth factor agents (anti-VEGF), and vitrectomy may also be considered for the treatment of complications of ocular ischemia [4,76]. Anticoagulation also has a role in addition to acetylsalicylic acid particularly when antiphospholipid antibodies are presented (5). Other therapies include plasmapheresis and plasma exchange have been reported, rapidly removing circulating immune complexes proposed but have limited success [78,79].

Hypertensive retinopathy: SLE patients are at risk for arterial hypertension. Many etiologies are involved such as increase in vascular stiffness due to endothelial dysfunction and atherosclerosis or renal disease, and secondary to medication such as cyclosporine and glucocorticoids [80,81]. Hypertensive retinopathy is a result of occlusion of retinal arterioles and consequent retinal infarction [5]. Proper medical management to control blood pressure and underlying SLE is the mainstay of the therapy.

Retinal vein occlusion and/or retinal artery occlusion: This is a rare form of retinal vascular disease that is often associated with poor visual prognosis [82]. There is an elevated risk for patients with SLE to develop retinal vascular occlusion [83]. In patients with both SLE and antiphospholipid antibodies, the pathogenesis of severe vaso-occlusive retinopathy is attributed to thrombosis associated with antiphospholipid syndrome, rather than the immune complex mediated vasculitis related to SLE [84]. Isolated retinal vein occlusion, retinal artery occlusion, or combine retinal artery and vein occlusion have been reported [82,85,86]. More details about role of antiphospholipid syndrome related to ocular manifestations will discuss later in this article.

Retinal vasculitis: Severe retinal vasculitis is a rare, but potentially blinding, complication of patients with SLE [87] (Figure 2). Treatment of this retinal manifestation is the treatment of the systemic disease [88].
Neuro-ophthalmic manifestations

Optic nerve: Optic nerve disease is a rare manifestation of SLE and consists of optic neuritis (Figure 4) and ischemic optic neuropathy [98]. The optic nerve damage is believed to be secondary to an occlusive vasculitis of the small arterioles of the nerve, which leads to demyelination and/or axonal necrosis [99,100]. Signs of optic nerve disease include reduced visual acuity, impairment of color vision, diminished light brightness sensitivity, decreased contrast sensitivity, afferent pupillary defect and visual field defects. Fundoscopy discloses a swollen disc except in the case of retrobulbar neuritis that is characterized by a normal appearing optic disc; optic atrophy also is seen [3]. Optic neuritis response very well to high dose corticosteroid treatment [101]. Treatment for lupus optic neuropathy is also with high dose corticosteroid but followed by an extended oral taper. Immunosuppressive agents have shown success in some studies [4]. Visual prognosis following optic neuropathy is generally poor [5].

Cranial nerve involvement: Eye movement abnormalities are common such as ocular motor nerve palsy and internuclear ophthalmoplegia. Ischemic microvascular disease of the brainstem is usually the etiology [4]. Lesions of the posterior visual pathway and retrochiasmal lesions are relatively rare but have been previously reported [100,102,103]. Patients can be presented with visual hallucination, nystagmus and cortical blindness [4]. Pupillary abnormalities such as light-near dissociation, Horner’s syndrome, Adie’s pupil have also been reported [5]. Other neuro-ophthalmic manifestations of SLE also include idiopathic intracranial hypertension, Miller-Fisher syndrome and Devic’s syndrome (neuromyelitis optica) [3].

Role of Antiphospholipid Syndrome

Risk of developing ocular occlusive vascular disease is higher in the patients with SLE and positive circulating antiphospholipid antibodies (aPL). Retinopathy including arterial and venous occlusion, cotton-wool spots, optic disk edema and hemorrhages reported to be higher among SLE patients at the presence of aPL compared with SLE patients who has negative antibody against aPL [104]. Similar ocular and neuro-ophthalmic manifestations also reported in both primary and secondary anti-phospholipid syndrome (APS) [8]. Anti-phospholipid syndrome is an autoimmune disease defined by presence of anti-phospholipid antibodies and with one the following clinical manifestation, venous and or arterial thrombosis and repetitive fetal
loss. Primary APS is diagnosed when no underlying disease is recognized whereas secondary APS occurs when the disease develop at the context of another autoimmune disease like systemic lupus erythematosus.

Although the definite mechanism has not been discovered yet, the presence of autoantibodies including lupus anticoagulant, anti-cardiolipin antibody or anti-β2 glycoprotein-1 antibody might play a role in causing hemostasis shift to pro-thrombotic state leading to arterial and venous thrombosis [105]. Pro-inflammatory cytokines and endothelin-1 (ET-1, an endothelium-derived contracting factor) might also be contributive factors in developing hypercoagulable condition in APS [106,107].

Ocular manifestation of APS syndrome include anterior eye segment, posterior eye segment and neuroophthalmic changes. Anterior segment manifest as telangiectasia, microanurysm, dry eye, episcleritis, scleritis, uveitis, keratitis and diplopia [108]. Unilateral and bilateral vascular retinal thrombosis is most prominent posterior segment ocular manifestation in both primary and secondary APS [109]. As mentioned before SLE patient with retinal vascular thrombosis reported to have higher level of aPL. These patients tend to develop central or branch artery and vein occlusion or with extensive retinal capillary non-perfusion complications including neovascularization, vitreous hemorrhage and tractional retinal detachment. Retinal vasculitis, vitiritis, posterior scleritis and central retinal artery occlusion also reported with higher prevalence in aPL positive patients [110-113]. APS associated neuro-ophthalmic changes are probably related to blood supply hazard and optic nerve demyelization and include anterior non-arterial ischemic neuropathy (NAION), retro-bulbar neuritis and orbital ischemic syndrome on catastrophic APS [114,115].

In general the presence of aPL in SLE patients is associated with focal thrombotic events that prompt use of anticoagulants adding to immunosuppressive. APS patients with no anticoagulation treatment are generally at higher risk for recurrent thrombosis. Anticoagulation with heparin administration followed by anticoagulant therapy (Warfarin, etc.) to keep INR>3 are recommended therapy of venous thrombosis [116]. Pan-retinal argon laser photocoagulation may also be used in cases of retinal venous thrombosis and presence of neovascularization, aiming at prevention of both new thrombosis and its complications.

Drug Related Ocular Manifestation

Drug-induced lupus erythematosus is a lupus-like syndrome related to continuous drug exposure and resolves after discontinuation of the offending drug. Ocular complications are rare in drug-induced lupus. Episcleritis reported as an ocular manifestation of drug induced lupus in patients treated with Infliximab [117]. Retinal vasculitis and occlusive disease as a consequence of hydralazine and procainamide have been also reported [5].

Agents used in treating SLE can be potentially harmful to the eyes. Corticosteroids are commonly used in SLE and may cause cataract formation and steroid induced hypertension and glaucoma. A corticosteroid-induced increased intra-ocular hypertension occurs in both systemic and topical steroid administration but is most commonly identified as a complication of topical corticosteroid. Risk factors include age, history of glaucoma or glaucoma suspect, first-degree relative with primary open angle glaucoma, high myopia, previous steroid response, type I diabetes and history of connective tissue disease (eg. rheumatoid arthritis) [118].

Ideally, patients requiring long-term systemic corticosteroid therapy should have glaucoma screening and those receiving 10 mg or more of prednisolone daily should have their intra-ocular pressure checked at 1, 3, and 6 months and 6 monthly thereafter [119]. If glaucoma is established or progressed, corticosteroid should be stopped. The chronic corticosteroid response usually resolves in 1-4 weeks. The management of irreversible steroid induced glaucoma is similar to management of Primary open angle glaucoma (POAG). Medical management includes topical beta-blockers, prostaglandin analogues, alpha agonists and oral carbonic anhydrase inhibitors. Filtration surgery or trabeculectomy are the surgical options for the patient with persistent raised intra-ocular pressure following cessation of corticosteroid and refractory to medical therapy.

Chloroquine (CQ) and Hydroxychloroquine (HCQ) potentially can cause serious retinal toxicity if high dose given over a long period of time. Corneal epithelial deposits (vortex keratopathy, verticillata) may develop in patients taking chloroquine, but very rarely impair the vision [120]. The retinal drug adverse effects include asymptomatic mild macular pigmentary changes, persistent paracentral visual field scotoma, color vision impairment and most typically paracentral degeneration surrounding the center of vision, called bull’s-eye maculopathy. Loss of visual sensitivity can be detected even before fundus exam changes, by careful testing of para-central vision. Widespread retinal pigment epithelium and optic nerve atrophy may progress in long-term drug exposure and can persist even after cessation of the drug [120].

The incidences of toxicity however in clinical practice are very small. Among 150,000 people who had taken hydroxychloroquine in the USA between 1960 and 2005, only 47 cases reported to develop hydroxychloroquine retinopathy [121]. The vast majority of reports of toxicity have occurred in individuals taking 6.5 mg/kg/day of HCQ or 3 mg/kg/day of CQ, for 5 years. Maintenance dose below this level is suggested if possible.

According to American Academy of Ophthalmology, screening by an ophthalmologist is recommended for those patients on hydroxychloroquine who are at higher risk: dose >6.5 mg/kg/day, duration of treatment >5 years and high risk patient with renal or hepatic disease, pre-existing retinal disease or age >60 years. New screening guideline is now recommending to perform fundus examinations with 10-2 automated fields and at least one objective test including multifocal electoretinogram, fundus autofluorescence or spectral domain optical coherence tomography (SD-OCT). A baseline examination along with annual screening should be initiated no later than 5 years after starting hydroxychloroquine therapy [122].

Ocular manifestations in SLE, pathology and treatment are summarized in Table 2.

New Treatment Modalities

The drugs commonly used in SLE are hydroxychloroquine and NSAIDs for mild disease activity/flare of malar rash, arthritis and fatigue. For moderate activity with arthritis, pleuritis, pericarditis, crops of mouth ulcers, rash up to two-ninths body surface area, early renal involvement; recommended treatments are corticosteroid alone or corticosteroid plus azathioprine or methotrexate or mycophenolate mofetil. For severe disease activity without renal involvement, which
are rash involving more than two-ninths body surface area, severe pleuritis, pericarditis, and cerebral features; higher dose of corticosteroid (orally or intravenously) plus mycophenolate mofetil or B-cell depletion or cyclophosphamide are recommended. Once there is renal involvement, which is presented with increased blood pressure, edema, and active urine sediment; corticosteroid with Euro-Lupus intravenous cyclophosphamide or mycophenolate mofetil or B-cell depletion are indicated [1].

<table>
<thead>
<tr>
<th>Location</th>
<th>Disease</th>
<th>Pathophysiology</th>
<th>Medication(s) other than systemic steroid</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extraocular</td>
<td>Eyelids</td>
<td>Discoid lupus</td>
<td>Hyperkeratotic epithelium, degeneration of basal layer, perivascular lymphocytic infiltration</td>
<td>Antimalarial therapy</td>
</tr>
<tr>
<td></td>
<td>Orbit</td>
<td>Periorbital edema/orbital masses/orbital myositis/panniculitis/orbital ischemia</td>
<td>Lymphocytic reaction, secondary vasculitis</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Lacrimal system</td>
<td>Dry eye syndrome ± secondary Sjögren syndrome</td>
<td>Lymphocytic infiltration of the exocrine glands</td>
<td>Artificial tears, topical corticosteroid, topical cyclosporine, tetracycline derivatives</td>
</tr>
<tr>
<td></td>
<td>Anterior eye segment</td>
<td>Conjunctiva</td>
<td>Conjunctivitis/symblepharon</td>
<td>Subepithelial and perivascular cellular infiltrate, granuloma formation, immunodeposits</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cornea</td>
<td>Punctate epithelial erosion/recurrent corneal erosion/PUK/IK</td>
<td>Immune complex deposition, vaso-occlusion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Episciera</td>
<td>Episcleritis</td>
<td>Topical/systemic NSAID</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sclera</td>
<td>Scleritis</td>
<td>Systemic NSAID</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Iris/ciliary body</td>
<td>Anterior uveitis</td>
<td>Topical steroid, Topical cycloplegic</td>
</tr>
<tr>
<td>Posterior eye segment</td>
<td>Retina/macula</td>
<td>SLE retinopathy/hypertensive retinopathy/retinal vascular occlusion/retinal vasculitis/maculopathy/macular ischemia</td>
<td>Activation of immune cells and cytokines, capillary endothelial damage, hyperviscosity</td>
<td>Anti-VEGF, ASA, anticoagulant</td>
</tr>
<tr>
<td></td>
<td>Choroid</td>
<td>Choroidopathy/PCV</td>
<td>Inflammatory cells, Ig, complement in choroidal vessel</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Optic nerve</td>
<td>Optic neuritis/ischemic optic neuropathy</td>
<td>Occlusive vasculitis, demyelination, axonal necrosis</td>
<td>-</td>
</tr>
<tr>
<td>Others</td>
<td>Pupil</td>
<td>Light-near dissociation/Horner’s syndrome/Adie’s pupil/</td>
<td>Ischemic microvascular disease</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Lens</td>
<td>Cataract</td>
<td>Steroid and other unknown mechanism</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Glaucoma</td>
<td>Open angle glaucoma/secondary angle closure glaucoma/steroid induced glaucoma</td>
<td>Multiple mechanism</td>
<td>Anti-glaucoma medication</td>
</tr>
<tr>
<td></td>
<td>Cranial nerve and posterior visual pathway</td>
<td>Ocular motor nerve palsies/internuclear ophthalmoplegia/one and a half syndrome/visual hallucination/nystagmus/cortical blindness/Miller-Fisher syndrome/Denic’s syndrome</td>
<td>Ischemic microvascular disease</td>
<td>-</td>
</tr>
</tbody>
</table>

Table 2: Ocular manifestations in SLE.

Patients who do not respond to conventional immunosuppressive drugs are considered for targeted biological therapies aimed at cytokines, B and T lymphocytes, and B-cell activating factors. These medications are rituximab (a chimeric monoclonal IgG1 antibody to CD20), belimumab (a monoclonal human antibody that inactivate BLyS or B-cell activating factor, BAFF), atacicept (blocks the interaction between BLyS and a proliferation-inducing ligand (APRIL) and their receptors), epratuzumab (a humanized anti-CD22 IgG1 antibody).
monoclonal antibody), abatacept (a biological drug that blocks T-cell co-stimulation), sifalimumab (a human anti-interferon α monoclonal antibody, binds and neutralizes most interferon α subtypes). (1) Other anti-interferon α molecules that have been going through testing in phase 2 studies are rontalizumab, AGS-009, MEDI-546 and interferon α kinoid [123].

Conclusion
SLE is a chronic, relapsing autoimmune connective tissue disease, primarily affecting skin, joints, kidneys, heart, lungs, nervous system, blood elements, and serosal membranes [6]. Eyes are not the main organ affected in SLE, but once it gets involved, it can lead to permanent eye damage and blindness. Many ocular complications and disease deterioration are preventable, treatable, or even curable, thus inter-department collaboration is highly important. Prompt treatment with high dose systemic corticosteroid and immunosuppressive therapy are necessary in many circumstances. Ocular complications should be aware of, and proper evaluation by ophthalmologists is essential.

Acknowledgement
The authors are thankful to Jamie L. Metzinger and Janine Preble for providing the necessary facilities for the preparation of the paper.

References


